Project Summary
In P02 we examine how oncogenic KRAS mutations influence hepatic stellate cells (HSCs) and metastasis-associated fibroblasts (MAFs) in colorectal liver metastases (CRLM). We will be using ex vivo co-culture systems with tumor organoids carrying different oncogenic mutations and validate our findings in established in vivo models. Additionally, we aim to explore how KRAS-G12D influences hepatic stellate cell conditioning in the premetastatic niche, to assess whether modifying MAF polarization, HSC conditioning, and oncogenic signalling could enhance immunotherapy for colorectal liver metastases.
